NCT03796351 - Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX® | Biotech Hunter

Enrollment

25

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Healthy Volunteers

Interventions

DRUG

MT10107

"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."

DRUG

Botox

"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."

Trial Locations (1)

Unknown

The Catholic University of Korea, St. Paul's Hospital, Seoul